Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 46

Results For "Eni"

2622 News Found

Novo Nordisk's Wegovy approved in the US for the treatment of MASH
News | August 19, 2025

Novo Nordisk's Wegovy approved in the US for the treatment of MASH

The accelerated approval is supported by results from part 1 of the ESSENCE trial


BioAge Labs doses first patient in BGE-102 phase 1 trial
Biotech | August 19, 2025

BioAge Labs doses first patient in BGE-102 phase 1 trial

The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants


From Policy to Practice: How India’s Pharmaceutical Industry is Being Shaped by the PLI Scheme – by Vikram Aditya Sehgal, Director – Finance, Centrient India
Opinion | August 18, 2025

From Policy to Practice: How India’s Pharmaceutical Industry is Being Shaped by the PLI Scheme – by Vikram Aditya Sehgal, Director – Finance, Centrient India

The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations


FDA grants breakthrough therapy designation to Ifinatamab Deruxtecan for lung cancer patients
Drug Approval | August 18, 2025

FDA grants breakthrough therapy designation to Ifinatamab Deruxtecan for lung cancer patients

Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo


Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr
News | August 17, 2025

Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr

Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent


QMS Medical Allied Services reports 31.65% rise in Q1 FY26 PAT to Rs. 3.15 Cr
News | August 17, 2025

QMS Medical Allied Services reports 31.65% rise in Q1 FY26 PAT to Rs. 3.15 Cr

The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth


Cohance Lifesciences reports 13% revenue growth in Q1 FY26
News | August 16, 2025

Cohance Lifesciences reports 13% revenue growth in Q1 FY26

During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site